GlaxoSmithKline PLC (GSK.LN) said Tuesday that it has generated promising new data from a study of a potential treatment for multiple myeloma, a cancer that affects blood cells in bone marrow.
The drug company said new data from the dose-expansion phase of its phase 1/2 study of GSK2857916 demonstrated a 60% response rate and median progression-free survival of 7.9 months in patients who had been heavily pre-treated.
GlaxoSmithKline said it was encouraged by the response rate seen in patients who had very limited options for further treatment. The company said it intends to rapidly progress development of the treatment, initiating pivotal monotherapy and new combination studies in 2018.
Write to Adam Clark at firstname.lastname@example.org; @AdamDowJones
(END) Dow Jones Newswires
December 12, 2017 02:41 ET (07:41 GMT)